Referring Clinicians

Trials Recruiting at ACTC 

Tumour StreamTrial NameStudy DescriptionKey Investigational AgentKey Inclusion CriteriaRecruitment Status
Multiple tumour streamGILEAD (GS-US-494-5484)A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in
Subjects with Advanced Solid Tumors
GS-4224 (small molecule oral PDL1 Inhibitor)Advanced Solid Organ Malignancy with no further treatment options.

TPS/CPS >10% on pre-screening of archival tissue
Biopsy sub-study Recruiting
Melanoma (Advanced/ Metastatic) MK1308-001A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in
Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
MK1308 (CTLA4 Inhibitor) +/- Pembrolizumab (6 weekly)Metastatic Melanoma with disease progression after PD1 or PDL1 checkpoint inhibitor therapyRecruiting
Merkel Cell CarcinomaMK-3475-913A phase 1 open label, multi-arm , multicenter study of MK-1308 in combination with pembrolizumab for subjects with advanced solid organ tumoursPembrolizumab(antiPD1)Unresectable Stage III and Stage IV Merkel Cell Carcinoma( 1st line)Recruiting
Melanoma, NSCLCNP40435Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumoursPD1/TIM3 bi-specific antibody-Melanoma: after PD1+/- CTLA4 inhibitor (includes uveal melanoma)
-NSCLC: CPI experienced, post platinum, must have received at least 4 months of CPI, PDL1>1%
Cervical SCCBP40234An Open Label Phase 2 Study Evaluating the activity of FAP-Interleukin2 Variant and Atezolizumab in advanced Solid Organ CancerAtezolizumab + FAP Interleukin2 Variant Second or subsequent line systemic therapy Recruiting

How to Refer 

Please email all referrals to (include Att: ACTC in email subject)

Email us for any other inquiries:


Auckland Cancer Trials Centre

Auckland City Hospital,

2, Park Road, Grafton,

1023, Auckland, New Zealand

Patient Referrals 

Please email all referrals to: (include Att: ACTC in email subject)

Email us for any other inquiries: